﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Addiction Medicine</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Addiction Medicine"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.28.26351962v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.25.26350029v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.17.26351044v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.23.26351366v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.17.26351089v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.13.26350800v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.15.26350988v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.14.26350880v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.10.26350655v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.11.26350657v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.03.26348150v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.04.01.26349949v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.26.26349460v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.17.26348617v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.16.26348531v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.15.26348438v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.13.26348339v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.12.26348300v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.03.26347368v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.23.26346644v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.27.26347207v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.24.26347002v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.19.26346573v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.16.26346428v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.16.26346220v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.12.26346211v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.12.26346166v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.10.26346048v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.05.26345663v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.03.26345434v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.28.26351962v1?rss=1">
<title>
<![CDATA[
A reliability-screened thalamocortical control-network phenotype tracks cocaine-use history in cocaine use disorder 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.28.26351962v1?rss=1
</link>
<description><![CDATA[
Background: A central goal in psychiatry is to move from symptom-defined diagnoses toward biologically interpretable and reliable phenotypes. In cocaine use disorder (CUD), many resting-state abnormalities have been reported, but few circuit-level findings have been explicitly screened for reliability. We tested whether prespecified thalamocortical features yield a reproducible phenotype in CUD and whether that phenotype reflects diagnosis, recent cocaine use, or longer-term illness history. Methods: Discovery analyses used resting-state data from 105 participants (46 healthy controls, 59 CUD). From a 13-region thalamocortical circuit, we derived an HC-trained LEiDA state model, generated 11 prespecified features, and advanced only those meeting split-half reliability criteria (ICC[3,1] [&ge;]0.40). A separate paired TMS sample (n=44) was used for extension analyses. Results: Five features survived reliability screening. Within CUD, longer duration since beginning cocaine use was associated with greater occupancy of a control-like state (standardized {beta}=0.37, q=0.005) and stronger whole-thalamus connectivity with control frontoparietal cortex (standardized {beta}=0.30, q=0.018). Neither days since last use nor CUD vs. healthy diagnosis were associated with any reliable feature after correction. Joint-history models indicated that the signal was better explained by longer-term use history than by recent use. Localization analyses indicated the connectivity effect was concentrated in dorsal thalamic regions. TMS-interaction and effective-connectivity follow-ups were null. Conclusions: Reliability screening identified a thalamocortical control-network phenotype in CUD that tracks longer cocaine-use history rather than diagnosis or recent use. More broadly, this workflow offers a practical framework for screening candidate circuit-level psychiatric phenotypes for reliability.
]]></description>
<dc:creator><![CDATA[ Edelman, B. B., Skolnick, J. ]]></dc:creator>
<dc:date>2026-04-29</dc:date>
<dc:identifier>doi:10.64898/2026.04.28.26351962</dc:identifier>
<dc:title><![CDATA[A reliability-screened thalamocortical control-network phenotype tracks cocaine-use history in cocaine use disorder]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.25.26350029v1?rss=1">
<title>
<![CDATA[
Family-supervised disulfiram as a culturally grounded model for alcohol use disorder treatment in Sri Lanka: a pilot randomized controlled trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.25.26350029v1?rss=1
</link>
<description><![CDATA[
ObjectivesTo evaluate the effectiveness and cultural feasibility of family-supervised disulfiram as a first-line treatment for alcohol use disorder (AUD) in Sri Lanka, and to compare its clinical outcomes with standard therapy delivered at a tertiary psychiatric unit.

DesignSingle-blind Randomized Controlled Trial known as ETAT-RCT (Efficacy of Two Alcohol Treatments) was conducted under routine clinical setup with three parallel groups: family-supervised disulfiram, locally developed psychosocial intervention, and routine treatment. Allocation was independently concealed; assessors were blinded. Analyses followed an intention-to-treat approach using repeated-measures ANOVA (group x time). This paper reports the disulfiram (test) versus routine treatment (control) comparison; the psychosocial intervention will be reported separately.

SettingUniversity Psychiatry Unit, National Hospital of Sri Lanka, Colombo (UPU, NHSLC).

ParticipantsPatients aged [&ge;]14 years with AUD presenting to the unit were recruited consecutively without inducements. Planned allocation ratio was 1:1:1 with 31 participants per arm; key exclusions were lifetime psychotic disorder and current contraindication to disulfiram.

RandomisationParticipants were randomised into each treatment arm using an independent concealed paper-based allocation system.

Intervention(1) family-supervised disulfiram, with psychoeducation/support only - DT arm, (2) a locally developed denormalization focused psychosocial programme - PT arm, and (3) standard therapy (motivational/cognitive/behavioural input; naltrexone permitted; no disulfiram/denormalisation) - ST arm.

Outcome measuresPrimary outcome was Alcohol Use Disorders Identification Test (AUDIT) score at 12 months. Key secondary outcomes were past 30 day alcohol use via Timeline Follow-Back (TLFB); alcohol biomarkers [ALT (alanine aminotransferase), {gamma}-GT (gamma-glutamyl transferase), MCV (mean corpuscular volume)]; locally developed measures of addiction-relevant cognitive, affective, behavioural factors [AARSU (Attitude Assessment Related to Substance Use), BARSU (Behaviour Assessment Related to Substance Use)]; and Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Outcomes were assessed at baseline, 6, and 12 months.

ResultsParticipants in DT (n=33) and ST (n=38) were comparable at baseline. Both groups showed clinically and statistically significant improvement in AUDIT scores over 12 months (DT: F=39.90, p<0.001; ST: F=49.90, p<0.001), with no groupxtime interaction (F<0.001, p=0.98). Biomarkers and AARSU, and BARSU and Q-LES-Q-SF to a lesser degree, mirrored the AUDIT pattern. TLFB did not change significantly over time in either arm (p>0.05). In moderator analyses, improvement in AUDIT was not moderated by baseline motivation (F=0.20, p=0.89) but was moderated by baseline AUD severity (F=7.70, p=0.007). No serious adverse events were attributed to disulfiram. Adherence to supervised dosing was generally high during periods of supervision but intermittent overall.

ConclusionsIn this pilot RCT, family-supervised disulfiram achieved 12-month outcomes comparable to standard therapy in a tertiary Sri Lankan setting. Improvements were independent of baseline motivation and varied by baseline AUD severity. These findings may support family-supervised disulfiram as a culturally feasible first-line option in Sri Lanka; larger, adequately powered multicentre trials are warranted to confirm effectiveness and scalability.

Trial registrationSLCTR/2014/021

Strengths and limitations of this studyO_LIThis pragmatic randomised controlled trial demonstrates an improved real world applicability and validity as it was conducted in an unmodified public-sector psychiatric setting.
C_LIO_LIStrong generalisability of the study with similar health systems due to broad eligibility criteria of patients warranted the inclusion of regular and general patient cohort with alcohol use disorders, strengthening generalisability within similar health systems.
C_LIO_LIInterventions were carried out without additional staff or patient monitoring reflecting routine clinical practice.
C_LIO_LIComprehensive assessment beyond abstinence alone with multidimensional outcomes such as alcohol related harm, biomarkers, cognitive behavioural change and quality of life.
C_LIO_LIMinor potential in performance bias due to the nature of intervention where blinding study subjects and clinicians is not feasible.
C_LIO_LISampling bias towards males and variability within the ST arm can affect the generalisability.
C_LI
]]></description>
<dc:creator><![CDATA[ Rajasuriya, M., Chulasiri, P., Ratnayake, P., Plevin, D. ]]></dc:creator>
<dc:date>2026-04-27</dc:date>
<dc:identifier>doi:10.64898/2026.04.25.26350029</dc:identifier>
<dc:title><![CDATA[Family-supervised disulfiram as a culturally grounded model for alcohol use disorder treatment in Sri Lanka: a pilot randomized controlled trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.17.26351044v1?rss=1">
<title>
<![CDATA[
Exploring the Relationship Between Non-Suicidal Self-Injury and Problematic Sexual Behaviour 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.17.26351044v1?rss=1
</link>
<description><![CDATA[
ObjectivesNon-suicidal self-injury (NSSI) and self-harming sexual behaviours share functional and behavioural overlaps. However, the relationship between NSSI and problematic sexual behaviour (PSB) remains underexplored. This study aimed to investigate the association between NSSI and PSB in two cohorts - a non-clinical university cohort and a clinical PSB patient cohort.

MethodsData were collected from 2,189 university participants and 477 clinical PSB patients. NSSI was assessed via self-report, and PSB was measured with the Sexual Addiction Screening Test-Revised (SAST-R) Core. The four core addictive dimensions of PSB: relationship disturbance, loss of control, preoccupation, and affect disturbance, were also evaluated. Logistic regression analyses were conducted to examine the association between PSB (presence/absence and severity) and NSSI, looking at effects of gender and contributions of addictive dimensions of PSB.

ResultsRates of NSSI were similar in the university (7.1%) and patient (5.7%) cohorts; stratified by gender, a higher proportion of women PSB patients had NSSI compared to in the university cohort (29.3% vs 9.3%). In the university group, who had milder PSB than patients, PSB was associated with NSSI (OR=2.11, p<0.001); a significant gender by PSB interaction was found showing that women with PSB were over four times more likely to have NSSI than men without PSB (OR=4.44, p=0.037). In contrast, PSB severity was not associated with NSSI in PSB patients (OR=1.10, p=0.25). Associations of the addictive dimensions of PSB with NSSI were observed only in the subgroup of university women, in the  preoccupation dimension (p<0.001).

ConclusionsOur findings highlight gender-specific patterns in the association between PSB and NSSI, suggesting the need for further research and possibly targeted prevention and intervention strategies in women.
]]></description>
<dc:creator><![CDATA[ Jiang, S., Foo, J. C., Roper, L., Yang, E., Green, B., Arnau, R., Behavioral Addictions Studies and Insights Consortium,, Lodhi, R. J., Isenberg, R., Wishart, D. S., Fujiwara, E., Carnes, P. J., Aitchison, K. J. ]]></dc:creator>
<dc:date>2026-04-25</dc:date>
<dc:identifier>doi:10.64898/2026.04.17.26351044</dc:identifier>
<dc:title><![CDATA[Exploring the Relationship Between Non-Suicidal Self-Injury and Problematic Sexual Behaviour]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.23.26351366v1?rss=1">
<title>
<![CDATA[
Regular cannabis use is associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.23.26351366v1?rss=1
</link>
<description><![CDATA[
Regular cannabis use has been associated with alterations in reward-related neural processes, yet findings remain inconsistent and the relationship between neural activity and behavioural performance is not fully understood. The present study aimed to characterise neural and behavioural correlates of reward processing in regular cannabis users (CU) compared with matched non-users (NU) using the Monetary Incentive Delay Task (MIDT).

Firstly, we assessed behavioural performance through reaction times, accuracy and monetary earnings to determine whether potential neural alterations were reflected in task performance. Secondly, focusing on reward-related brain regions, we examined group differences in BOLD functional MRI activity during anticipation and outcome phases separately for monetary win and loss conditions. Finally, we explored the association between behavioural performance and neural activation. Our findings indicate that regular cannabis use is associated with altered engagement of key nodes within the mesocorticolimbic circuit during both anticipatory and outcome phases of reward processing, accompanied by impaired behavioural performance. Particularly, compared with NU, CU showed (I) lower striatal activity during anticipation of monetary win and higher ventral striatum and frontal pole activity during anticipation of monetary loss; (II) greater VTA activation during outcome of successful monetary win and loss avoidance and lower frontal pole activity during outcome of unsuccessful loss avoidance; (III) impaired behavioural performance, reflected in lower monetary rewards and a trend towards slower reaction times and reduced accuracy; (IV) disrupted brain-behaviour coupling.

Results from this study may help inform future research on the neurobiological mechanisms underlying changes in reward function and the resultant behavioural consequences of cannabis use.
]]></description>
<dc:creator><![CDATA[ Lombardi, G., Blest-Hopley, G., Tarantini, M. M., O'Neill, A., Wilson, R., O'Daly, O., Giampietro, V., Bhattacharyya, S. ]]></dc:creator>
<dc:date>2026-04-24</dc:date>
<dc:identifier>doi:10.64898/2026.04.23.26351366</dc:identifier>
<dc:title><![CDATA[Regular cannabis use is associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.17.26351089v1?rss=1">
<title>
<![CDATA[
Indirect Genetic Effects on Alcohol Use Disorder and Nicotine Dependence 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.17.26351089v1?rss=1
</link>
<description><![CDATA[
Substance use disorders run in families, yet the mechanisms underlying intergenerational transmission remain unclear. We investigated indirect genetic effects, pathways through which parental genotypes influence offspring phenotypes via the family environment, for alcohol use disorder (AUD), nicotine dependence (ND), and related quantitative outcomes, and aimed to identify family environmental factors through which such effects may operate. Using transmitted and non-transmitted polygenic scores (PGS) constructed for problematic alcohol use, tobacco use disorder, and general addiction liability, we analyzed 5972 European-ancestry adult offspring with at least one genotyped parent from the population-based Lifelines cohort (Netherlands). Offspring outcomes included lifetime DSM-5 AUD diagnosis, AUD symptom count, maximum drinks in 24 hours, Fagerstrom Test for Nicotine Dependence score, and cigarettes per day. AUD findings were meta-analyzed with data from the Brisbane Longitudinal Twin Study (N = 1368; Australia). We also examined parent-of-origin effects and mediation by parental substance use and socioeconomic status using structural equation modeling. Transmitted PGS robustly predicted all AUD and ND outcomes ({beta} = 0.07-0.16; OR = 1.20 for AUD diagnosis). Non-transmitted PGS, indexing indirect genetic effects, were negligible for all clinical syndrome outcomes. The only significant indirect genetic effect was on cigarettes per day ({beta} = 0.03, p = 0.01), mediated by parental smoking behavior but not socioeconomic status. These findings indicate that intergenerational transmission of risk for AUD and ND is driven primarily by direct genetic effects, with modest indirect genetic effects on smoking quantity. Larger samples and cross-trait analyses are needed to further elucidate these mechanisms.
]]></description>
<dc:creator><![CDATA[ Luo, M., Trindade Pons, V., Zakharin, M., Pingault, J.-B., Gillespie, N. A., van Loo, H. M. ]]></dc:creator>
<dc:date>2026-04-19</dc:date>
<dc:identifier>doi:10.64898/2026.04.17.26351089</dc:identifier>
<dc:title><![CDATA[Indirect Genetic Effects on Alcohol Use Disorder and Nicotine Dependence]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-19</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.13.26350800v1?rss=1">
<title>
<![CDATA[
Adiposity and inflammation mediate altered metabolic profiles in individuals with opioid use disorder 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.13.26350800v1?rss=1
</link>
<description><![CDATA[
Previous studies have linked opioid use to altered metabolic profiles, but findings have been inconsistent and mechanisms remain unclear. One potential mechanism involves increased adiposity, leading to chronic low-grade inflammation that elevates metabolic risk. Here, we examined metabolic profiles in individuals with opioid use disorder (OUD) and matched non-OUD controls, focusing on the sequential mediating roles of BMI and inflammation. Data from individuals with OUD (n=281) and non-OUD (n=246) were drawn from a natural history screening protocol from the National Institute on Alcohol Abuse and Alcoholism intramural program. Groups were matched on age, sex, race, ethnicity, socioeconomic status, and education via propensity score matching. Metabolic measures included BMI, blood glucose, hemoglobin A1c (HbA1c), and lipid profiles, with lipid imbalance indexed by the atherogenic index of plasma (AIP). Inflammatory markers included C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Individuals with OUD had significantly higher BMI (F1,481=12.9, p<0.001), HbA1c (F1,481=10.5, p=0.001), lower high-density lipoprotein cholesterol (HDL-C; F1,481= 46.2, p< 0.001), higher low-density lipoprotein cholesterol (LDL-C; F1, 481=11.9, p< 0.001), and higher AIP (F1,481=20.7, p< 0.001) compared to non-OUD. Inflammatory markers were also elevated in individuals with OUD, including CRP (F1,481=9.4, p=0.002) and ESR (F1,481=7.4, p= 0.007), and statistically mediated group differences in AIP and HbA1c, respectively. Our results are consistent with prior evidence of metabolic dysfunctions in individuals with OUD and suggest inflammation as a contributing mechanism. Targeting metabolic health and inflammation may offer new avenues for improving long-term health outcomes in OUD.
]]></description>
<dc:creator><![CDATA[ Li, X., Manza, P., Wang, G.-J., Giddens, N., Belcher, A., Schwandt, M., Diazgranados, N., Lynch, K. G., Volkow, N. D., Shi, Z., Wiers, C. E. ]]></dc:creator>
<dc:date>2026-04-18</dc:date>
<dc:identifier>doi:10.64898/2026.04.13.26350800</dc:identifier>
<dc:title><![CDATA[Adiposity and inflammation mediate altered metabolic profiles in individuals with opioid use disorder]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.15.26350988v1?rss=1">
<title>
<![CDATA[
A Machine Learning Based Causal Interface for Time-Varying Environmental Predictors of Substance Use Initiation in the ABCD Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.15.26350988v1?rss=1
</link>
<description><![CDATA[
BackgroundThe Adolescent Brain Cognitive Development (ABCD) Study(R) offers rich longitudinal data on environmental, genetic, and other factors related to substance use initiation. Classical marginal structural models (MSMs) require selecting covariates for propensity models, which is challenging in the presence of hundreds of correlated predictors.

MethodsWe analyzed longitudinal panel data from 11,868 ABCD participants, where each individual contributed repeated observations over time. Interval-level binary outcomes were defined for initiation of alcohol, nicotine, cannabis, and any substance, restricting analyses to participants at risk prior to initiation. All predictors were constructed as lagged variables to preserve temporal ordering. We implemented a two-stage machine learning-based causal framework. First, we performed graph discovery using a Granger-inspired lagged predictive modeling approach, applying elastic-net logistic regression to identify predictive relationships between lagged environmental variables and future initiation outcomes. Robust candidate edges were selected using subject-level bootstrap stability selection. Second, we estimated adjusted effect sizes for stable edges using double machine learning (DML)-style partialling-out with cross-fitting. For each candidate predictor, the treatment was defined as the lagged variable of interest and adjusted for high-dimensional lagged covariates. Cross-fitting with group-based splitting accounted for within-subject dependence, and nuisance functions were estimated using random forest models. Cluster-robust standard errors were used for inference.

ResultsWe identified a set of stable predictors across multiple domains, including sleep patterns, family environment, peer relationships, behavioral traits, and genetic risk. Many predictors were shared across substance outcomes, while some were outcome-specific. Estimated effect sizes were modest, typically ranging from -0.01 to 0.02 per standard deviation increase in the predictor. Both risk-increasing and protective associations were observed. Risk factors included sleep disturbance and behavioral risk indicators, while protective factors included parental monitoring and structured environments.

ConclusionsThis study provides a practical framework for analyzing high-dimensional longitudinal data and identifying time-varying predictors of substance use initiation. The approach combines machine learning for variable selection with causal inference methods for effect estimation. The results highlight both shared and substance-specific risk factors and identify modifiable targets, such as family environment and sleep, that may inform prevention strategies.
]]></description>
<dc:creator><![CDATA[ Wei, M., Yadlapati, L., Peng, Q. ]]></dc:creator>
<dc:date>2026-04-17</dc:date>
<dc:identifier>doi:10.64898/2026.04.15.26350988</dc:identifier>
<dc:title><![CDATA[A Machine Learning Based Causal Interface for Time-Varying Environmental Predictors of Substance Use Initiation in the ABCD Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.14.26350880v1?rss=1">
<title>
<![CDATA[
Stakeholder views on implementing a novel addiction screening and prevention tool in a hospital setting: A qualitative study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.14.26350880v1?rss=1
</link>
<description><![CDATA[
IntroductionCurrent best practice is for primary care physicians (PCPs) to screen patients for problematic substance use at checkups. However, this practice is not routine, is done in an unstandardized manner, and contributes to the overburdening of PCPs. Screening practices also target current, potentially problematic use behaviors, thus limiting their capacity to help patients prevent problems before they start. Recent scientific advances in identifying people at high risk for substance use problems as a means of facilitating prevention efforts have not yet been integrated into medical practice. To address these issues, our research team developed a freestanding platform called the Comprehensive Addiction Risk Evaluation System (CARES). CARES provides personalized information about genetic and behavioral/environmental risk for substance use disorder (SUD) and connects individuals to resources based on their risk profile. The present study evaluated the potential for adoption and implementation of CARES within a health care system through qualitative interviews with key stakeholders.

MethodsSemi-structured interviews were developed using the Consolidated Framework for Implementation Research (CFIR) and conducted with N=15 interviewees. Transcripts were analyzed using rapid qualitative analysis.

ResultsKey themes included perceived need for new SUD screening tools, current SUD screening procedures and their pros/cons, openness to new ideas and clinical tools, fit of CARES with organizational goals and priorities, considerations for use of CARES with adolescent populations, anticipated patient response to CARES, barriers to implementation and uptake of CARES, changes required for implementation, and possibility for medical record integration. Interviewees generally expressed need for new screening tools and openness to using new tools, but expressed concern that existing provider burden, lack of SUD knowledge, and discomfort/stigma could stymie efforts to implement CARES.

Conclusions.There is a clear need for a low-burden, easy-to-use tool for substance use screening. CARES appears to be an acceptable and feasible approach to fill this gap. These findings will be used to inform pilot implementation of CARES in a clinical care setting.
]]></description>
<dc:creator><![CDATA[ Dash, G. F., Balcke, E., Poore, H., Dick, D. ]]></dc:creator>
<dc:date>2026-04-16</dc:date>
<dc:identifier>doi:10.64898/2026.04.14.26350880</dc:identifier>
<dc:title><![CDATA[Stakeholder views on implementing a novel addiction screening and prevention tool in a hospital setting: A qualitative study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-16</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.10.26350655v1?rss=1">
<title>
<![CDATA[
Dynamic and Baseline Multi-Task Learning for Predicting Substance Use Initiation in the ABCD Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.10.26350655v1?rss=1
</link>
<description><![CDATA[
BackgroundEarly initiation of substance use is linked to later adverse outcomes, and risk factors come from multiple domains and are shared across substances. In our previous work, traditional time-to-event Cox models identified individual risk factors, but these models are not designed to jointly model multiple outcomes or capture complex non-linear relationships. Multi-task learning (MTL) can leverage shared structure across related outcomes to improve prediction and distinguish common versus substance-specific predictors. However, most MTL studies rely on baseline features and focus on single outcomes, which limits their ability to capture shared risk and temporal changes. Substance use initiation is a time-dependent process that unfolds during development and reflects changing exposures over time. Baseline-only models cannot capture these changes or represent risk dynamics. Discrete-time modeling provides a practical approach by estimating interval-level initiation risk and combining it into cumulative risk at the subject level. By integrating multi-task learning with dynamic modeling, it is possible to share information across outcomes while capturing how risk evolves over time, which may improve prediction performance.

MethodsUsing the Adolescent Brain Cognitive Development (ABCD) Study(R) (release 5.1), we developed two complementary multi-task learning (MTL) frameworks to predict initiation of alcohol, nicotine, cannabis, and any substance use. A baseline MTL model predicted fixedhorizon (48-month) initiation using one record per participant, while a dynamic discrete-time MTL model incorporated longitudinal interval data to model time-varying risk. Both models used multi-domain environmental exposures, core covariates, and polygenic risk scores (PRS). Performance was evaluated on a held-out test set using AUROC, PR-AUC, and calibration metrics, and compared with single-task logistic regression (LR). Feature importance was assessed using permutation importance and compared with Cox proportional hazards models.

ResultsMTL showed comparable or improved performance relative to LR, with larger gains for low-prevalence outcomes (cannabis and nicotine). Incorporating longitudinal information led to consistent improvements across all outcomes. Dynamic models increased AUROC by +0.044 to +0.062 for MTL and +0.050 to +0.084 for LR, indicating that temporal information was the primary driver of performance gains. Feature importance analyses showed modest overlap across methods, with higher agreement between dynamic MTL and Cox models than static MTL. A small set of features, including externalizing behavior, parental monitoring, and developmental factors, were consistently identified across all approaches.

ConclusionsDynamic multi-task learning improves the prediction of substance use initiation by leveraging longitudinal structure and shared information across outcomes. While MTL provides additional gains, incorporating time-varying information is the dominant factor for improving performance. Combining baseline and dynamic frameworks offers a comprehensive strategy for identifying robust risk factors and modeling adolescent substance use initiation.
]]></description>
<dc:creator><![CDATA[ Wei, M., Zhang, H., Peng, Q. ]]></dc:creator>
<dc:date>2026-04-13</dc:date>
<dc:identifier>doi:10.64898/2026.04.10.26350655</dc:identifier>
<dc:title><![CDATA[Dynamic and Baseline Multi-Task Learning for Predicting Substance Use Initiation in the ABCD Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.11.26350657v1?rss=1">
<title>
<![CDATA[
Drug Checking Services in Latin America vs. the United States: Staff Perspectives, Program Characteristics, and Barriers to Implementation 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.11.26350657v1?rss=1
</link>
<description><![CDATA[
BackgroundDrug checking services (DCS) promote drug supply awareness among people who use drugs (PWUD) by detecting adulterants such as fentanyl and xylazine that are associated with overdose morbidity and mortality. However, there is limited research on DCS implementation in Latin America (LA).

MethodsWe conducted a survey of 38 DCS across LA (n=10) and the US (n=28) and compared program characteristics and barriers between these two regions. We also conducted a focus group discussion (FGD) with staff representing six organizations implementing DCS in LA. FGD themes were mapped to constructs quantitatively assessed in the survey.

ResultsCompared to US DCS, LA DCS more frequently reported funding gaps as a major implementation barrier (80% vs. 54%), law enforcement confiscating DCS supplies (38% vs. 11%), as well as offering supervised drug consumption (30% vs. 4%) and mental health/counseling (40% vs. 18%), but less frequently reported that DCS equipment was legal (44% vs. 75%). DCS on the Mexico-US border focused on people who inject drugs and offered syringe services, supervised consumption, and rapid sexually transmitted infection testing. DCS in central Mexico, Colombia, Peru, and Chile primarily provided DCS for the nightlife community (e.g., attendees of concerts/raves). Barriers to DCS implementation cited by FGD discussants included inadequate funding, DCS legal ambiguities, lack of government support, and cartel violence.

ConclusionDCS in LA would benefit from increased funding, government support, and a more permissive legal environment, thereby strengthening harm reduction efforts and improving safety for PWUD.
]]></description>
<dc:creator><![CDATA[ Bird, J. A., Rosen, J. G., Lira, J. A. S., Green, T. C., Park, J. N. N. ]]></dc:creator>
<dc:date>2026-04-13</dc:date>
<dc:identifier>doi:10.64898/2026.04.11.26350657</dc:identifier>
<dc:title><![CDATA[Drug Checking Services in Latin America vs. the United States: Staff Perspectives, Program Characteristics, and Barriers to Implementation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.03.26348150v1?rss=1">
<title>
<![CDATA[
Network and receptor architectures shape brain morphometry in addiction 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.03.26348150v1?rss=1
</link>
<description><![CDATA[
Substance use disorders (SUD) are chronic conditions with devastating effects on brain health, functioning, and survival. In this study, we compared brain morphometry of 2,782 individuals with SUD to 1,951 controls and assessed the topographic overlap of these differences with brain connectivity and receptor architecture. Across SUD, we identified a morphometric signature involving frontal, parietal, temporal and limbic systems that overlapped with cortical hub regions and harbored cortical and subcortical disease epicenters. Findings were highly consistent across six substances and numerous robustness and generalizability analyses. Transdiagnostic comparisons showed high spatial overlap of SUD epicenters with those of schizophrenia and bipolar disorder, suggesting shared network-constrained cortical differences. Finally, multivariate mapping revealed that SUD brain differences aligned with two neurotransmitter axes contrasting cannabinoid-opioid and dopaminergic systems. These findings indicate that addiction-related brain differences are shaped by connectome and neurotransmitter architecture, positioning brain network and neurochemical organization as key principles of SUD-related brain alterations.
]]></description>
<dc:creator><![CDATA[ Georgiadis, F., Milano, B. A., Lariviere, S., Hutchinson, K. E., Calhoun, V., Li, C.-S. R., Momenan, R., Sinha, R., Veltman, D., van Holst, R., Goudriaan, A., Luijten, M., Groefsema, M., Walter, H., Lett, T., Wiers, R., Schmaal, L., Flanagan, J., Porjesz, B., Ipser, J., Boehmer, J., Canessa, N., Salas, R., London, E., Paulus, M., Stein, D., Brooks, S., Reneman, L., Schrantee, A., Filbey, F., Hester, R., Yucel, M., Lorenzetti, V., Solowij, N., Martin-Santos, R., Batalla, A., Cousijn, J., Pomarol-Clotet, E., Garza-Villarreal, E. A., Leyton, M., Stein, E., Crunelle, C. L., Kaag, A. M., Verdejo-Ga ]]></dc:creator>
<dc:date>2026-04-06</dc:date>
<dc:identifier>doi:10.64898/2026.04.03.26348150</dc:identifier>
<dc:title><![CDATA[Network and receptor architectures shape brain morphometry in addiction]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.04.01.26349949v1?rss=1">
<title>
<![CDATA[
Chinese College Student Gamers Cohort (CCSGC): Multimodal Longitudinal Insights into Internet Gaming Disorder's Biopsychosocial Mechanisms and Risk Trajectories 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.04.01.26349949v1?rss=1
</link>
<description><![CDATA[
Internet gaming disorder (IGD) presents a significant public health challenge, yet its complex biopsychosocial mechanisms and dynamic risk trajectories remain poorly understood due to a scarcity of comprehensive longitudinal and multimodal cohorts. To address this critical gap, we established the Chinese College Student Gamers Cohort (CCSGC), a prospective, multimodal longitudinal study of 793 first-year undergraduates primarily playing Honor of Kings from 2022 Sept. The CCSGC integrates semi-annual psychosocial questionnaires, annual neuroimaging (EEG/fMRI), and biospecimen collection over multiple years. Baseline data revealed individuals with IGD (n=211) exhibited significantly higher gaming craving, psychological distress (depression, anxiety), impulsivity, and maladaptive motivational features compared to non-IGD gamers (regular players (RP) n=400; casual players (CP) n=182). Longitudinal analyses across four waves indicated bidirectional temporal associations between IGD severity and mental symptoms, and a stabilization of IGD incidence after an initial decrease. Furthermore, specific neurophysiological (e.g., N400 amplitude to game cues) and neuroimaging (e.g., superior parietal activation) markers were identified that correlated with IGD severity and predicted one-year outcomes in gaming disorder or social functioning. The CCSGC provides an invaluable resource for dissecting the heterogeneity, comorbidity, and intricate biopsychosocial mechanisms of IGD, holding significant potential to advance risk prediction, early identification, and targeted intervention strategies.
]]></description>
<dc:creator><![CDATA[ Yuchen, H., Guangdong, Z., Yifan, L., Shitong, X., Qihong, Z., Zifeng, W., Yixuan, S., Wangyue, L., Taoyu, W., Shiqiu, M., Yanhui, L., Tianye, J., Jie, S., Yan, S. ]]></dc:creator>
<dc:date>2026-04-01</dc:date>
<dc:identifier>doi:10.64898/2026.04.01.26349949</dc:identifier>
<dc:title><![CDATA[Chinese College Student Gamers Cohort (CCSGC): Multimodal Longitudinal Insights into Internet Gaming Disorder's Biopsychosocial Mechanisms and Risk Trajectories]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-04-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.26.26349460v1?rss=1">
<title>
<![CDATA[
Can Dietary Fibre Intake Reduce the Risk of Mental and Behavioral Disorders Due to Use of Tobacco in Smokers? 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.26.26349460v1?rss=1
</link>
<description><![CDATA[
Background and aimsMental and behavioral disorders due to use of tobacco (MBDT) present a critical challenge to global health, yet modifiable lifestyle factors for reducing its risk remain poorly understood. Given that dietary fibre can affect mental health through gut-brain communication, we sought to explore how fibre intake relates to MBDT risks in smokers.

MethodsWe specifically evaluated the link between dietary fibre intake and MBDT within a smoking population. Utilizing the UK Biobank (UKB) database, we performed cross-sectional (N=19,943) and prospective cohort (N=19,885) evaluations applying logistic and Cox proportional hazards models, respectively. To determine potential causality, two-sample Mendelian randomization (MR) was applied, relying on GWAS summary data derived from the IEU Open GWAS Project and FinnGen repositories.

ResultsCross-sectional findings indicated that individuals in the top quartile (Q4) of fibre intake exhibited decreased MBDT risks relative to the bottom quartile (Q1) (OR: 0.32, 95% CI: 0.13-0.79). Over a median observation time of 12.84 years, the prospective evaluation demonstrated a notable inverse correlation (Q4 HR: 0.46, 95% CI: 0.40-0.54). Non-linear modeling via restricted cubic splines uncovered an L-shaped dose-response curve. Furthermore, MR results confirmed a genetically predicted protective causality (IVW OR: 0.68, 95% CI: 0.49-0.95), which remained consistent across sensitivity validations.

ConclusionsAmong smokers, higher dietary fibre intake is robustly associated with a reduced risk of mental and behavioral disorders due to the use of tobacco, offering a modifiable dietary target for public health interventions.
]]></description>
<dc:creator><![CDATA[ Qi, X., Qi, H., li, N., Wang, T., Wang, W., Song, X., Mi, B., Zhang, D. ]]></dc:creator>
<dc:date>2026-03-28</dc:date>
<dc:identifier>doi:10.64898/2026.03.26.26349460</dc:identifier>
<dc:title><![CDATA[Can Dietary Fibre Intake Reduce the Risk of Mental and Behavioral Disorders Due to Use of Tobacco in Smokers?]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-28</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.17.26348617v1?rss=1">
<title>
<![CDATA[
Effectiveness of the Smoke Free App for Smoking Cessation -- Results of RAUCHFREI, a Randomised, Double-blind, Controlled, Two-arm, Parallel, Nationwide, Decentralised, Fully Remote Clinical Trial in Germany 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.17.26348617v1?rss=1
</link>
<description><![CDATA[
ObjectivesUptake of evidence-based smoking cessation support remains limited. Digital interventions offer the prospect of scalable and highly accessible support. Smoke Free, a digital mobile application using established behaviour change techniques, has shown promise, but no large-scale randomised controlled efficacy trial has yet been conducted. We assessed its effectiveness for smoking cessation.

DesignIn this prospective, randomised, controlled, two-arm, parallel clinical trial with 6-month follow-up, study personnel and patients were blinded.

SettingThe trial was conducted nationwide in Germany, utilising a decentralised, fully remote trial design. Enrolment took place digitally after receiving brief advice from a healthcare professional, following guidelines for primary care.

ParticipantsOut of a volunteer sample of 1850 patients assessed for eligibility, 1466 adult cigarette smokers who had at least moderate cigarette dependence (F17.2, FTCD[&ge;]3) were recruited between August 2023 and February 2024; 84.1% (1233 participants) completed the primary outcome measure.

InterventionsThe intervention group (IG) received the Smoke Free app including behaviour-change missions and gamification elements, while the control group (CG) received a text-only cessation information app. Both groups received brief advice from a healthcare professional.

Main outcome measuresThe prespecified primary outcome was self-reported 7-day point-prevalence abstinence from combustible tobacco at 6 months post-randomisation; secondary outcomes included biochemical validation of abstinence in participants providing a saliva sample (59% of eligible participants).

ResultsSelf-reported abstinence (primary outcome) was significantly higher in the IG compared with the CG (283 [39.3%] vs. 182 [24.4%], OR=2.01, 95% CI 1.60 to 2.50, p<0.0001). The NNT was 6.7 (5.1 to 9.8). The effect was consistent with biochemical validation (OR=1.76, 95% CI 1.27 to 2.44, p<0.0001) and across secondary outcomes and sensitivity analyses. The 6-month follow-up rates for the primary outcome did not differ between groups (IG: 601 [83.5%]; CG: 632 [84.7%]; p=0.52). Eighty-four serious adverse events were reported by 75 participants (IG: 31, 4.3%; CG: 44, 5.9%; p=0.53); none were treatment-related.

ConclusionsThe Smoke Free app is effective for aiding smoking cessation in at least moderately dependent cigarette smokers compared with an informational app when provided as an adjunct to brief advice from a healthcare professional.

Trial registrationThe trial was registered with the German Clinical Trials Register (DRKS00031140).

FundingSmoke Free 23 GmbH (for-profit company).
]]></description>
<dc:creator><![CDATA[ Keller, L., Schraplau, A., Timpel, P., Schönfelder, T., Scheibe, S., Heinrich, R., Bricker, J. B., Brown, J., Naughton, F., Raupach, T., West, R., Pontes da Silva, B., Schmidt-Lucke, C., Crane, D. ]]></dc:creator>
<dc:date>2026-03-19</dc:date>
<dc:identifier>doi:10.64898/2026.03.17.26348617</dc:identifier>
<dc:title><![CDATA[Effectiveness of the Smoke Free App for Smoking Cessation -- Results of RAUCHFREI, a Randomised, Double-blind, Controlled, Two-arm, Parallel, Nationwide, Decentralised, Fully Remote Clinical Trial in Germany]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-19</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.16.26348531v1?rss=1">
<title>
<![CDATA[
Preliminary investigation of between-network connectivity and craving during early alcohol abstinence 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.16.26348531v1?rss=1
</link>
<description><![CDATA[
BackgroundAlcohol use disorder (AUD) is a chronic condition characterized by compulsive drinking and high relapse risk. Craving in early abstinence is a strong predictor of relapse, yet its underlying neurobiological mechanisms remain unclear. Guided by Menons Triple Network Model (TNM) of psychopathology, this study investigates whether altered connectivity between the salience (SN), default mode (DMN), and central executive (CEN) networks --previously implicated in alcohol-related behaviours -- underlies craving during early abstinence.

MethodsA final cohort of 27 individuals with AUD recruited from an inpatient alcohol withdrawal program completed resting-state fMRI scans on day 1 of withdrawal and 18 days later. Additionally, 17 healthy controls underwent fMRI at two sessions spaced two weeks apart. Craving was assessed in the AUD group at both timepoints using the obsessive thoughts subscale of the Obsessive Compulsive Drinking Scale (OCDS). Functional connectivity between brain networks was computed by referencing each individuals between-network connectivity to normative models derived from large-scale reference data to generate scores reflecting their deviations from normative values.

Proposed analysesPlanned analyses will leverage large-scale lifespan normative models to test associations between patient deviation scores in SN-DMN connectivity and craving during acute withdrawal, along with longitudinal associations during abstinence. Exploratory analyses will assess correlations between craving and connectivity of other network pairs of the TNM.

ConclusionsThis report aims to identify functional neurobiological markers of craving during early abstinence in AUD employing normative models. Findings may advance understanding of relapse vulnerability and inform personalized interventions targeting large-scale brain network dysfunctions in AUD. This submission corresponds to Level 3 of the Peer Community In (PCI) Registered Report bias-control taxonomy: data were collected and pre-processed prior to hypothesis formulation, but key variables (subject-level values) have not been observed and no statistical analyses have been performed.
]]></description>
<dc:creator><![CDATA[ Salavrakos, M., Kumar, P., Cohen-Gilbert, J. E., Korponay, C., Hannon, K. A., Dricot, L., de Timary, P., Nickerson, L. D. ]]></dc:creator>
<dc:date>2026-03-17</dc:date>
<dc:identifier>doi:10.64898/2026.03.16.26348531</dc:identifier>
<dc:title><![CDATA[Preliminary investigation of between-network connectivity and craving during early alcohol abstinence]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.15.26348438v1?rss=1">
<title>
<![CDATA[
Racial and Ethnic Differences in Pregnancy Associated Overdose Mortality in the United States, 2016 to 2022 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.15.26348438v1?rss=1
</link>
<description><![CDATA[
Pregnant and postpartum people who use drugs in the United States are trying to survive at the intersection of two of the gravest public health crises of the 21st century US: epidemics of (1) maternal mortality and (2) the overdose epidemic. Although extensive evidence documents racial/ethnic disparities in each of these epidemics separately, comparatively little research has characterized racial/ethnic patterns in their collision, that is, in maternal overdose mortality. We analyzed individual-level mortality records from the National Vital Statistics System (NVSS) for 2016-2022 to describe racial/ethnic disparities in pregnancy-associated overdose deaths (PA-OD) and pregnancy-associated substance use disorder-related deaths (PA-SUD). Racial/ethnic-specific mortality rates were calculated per 100,000 live births with exact Poisson confidence intervals. Temporal trends were summarized using annual percent change (APC), and disparities were quantified using rate ratios and differences relative to non-Hispanic White individuals.

Overdose-related maternal mortality increased substantially during the study period across multiple racial and ethnic groups. Rates increased nearly threefold among non-Hispanic White individuals and rose more steeply among non-Hispanic Black individuals, producing a Black-White disparity that emerged over time. Rates among Hispanic individuals remained lower but increased rapidly, while estimates among American Indian and Alaska Native individuals were often high but unstable because of small counts. Substance use disorder-related maternal mortality exhibited a pronounced surge during 2019-2021 across several racial and ethnic groups.

These findings highlight rapidly evolving racial/ethnic patterns in maternal overdose mortality and underscore the need for targeted prevention and harm-reduction strategies to reduce overdose-related deaths during pregnancy and the postpartum period.

FundingWe are grateful to the following NIH grants for supporting this research: U54HD113292 and R01DA059182.
]]></description>
<dc:creator><![CDATA[ Cooper, H. L., Peterson, E. N., Kramer, M. R. ]]></dc:creator>
<dc:date>2026-03-17</dc:date>
<dc:identifier>doi:10.64898/2026.03.15.26348438</dc:identifier>
<dc:title><![CDATA[Racial and Ethnic Differences in Pregnancy Associated Overdose Mortality in the United States, 2016 to 2022]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.13.26348339v1?rss=1">
<title>
<![CDATA[
Salient cue reactivity and eating behaviours in ex-smokers, abstinent alcohol use disorder and obesity 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.13.26348339v1?rss=1
</link>
<description><![CDATA[
IntroductionNeural cue reactivity is increasingly being investigated as a biomarker of treatment response and relapse prediction in addiction disorders. Whilst aberrant brain responses to salient cues (e.g. drugs) have been widely reported in addiction, it is unclear whether these brain responses persist during longer-term abstinence, how they compare between substance use disorder and obesity, and relate to potential differences in eating behaviours. As part of the Gut Hormones in ADDiction (GHADD) neuroimaging study, we investigated how salient cue reactivity to drugs or food, craving and eating behaviours compare in three clinical populations where alterations have been previously observed: abstinent nicotine use disorder (NUD) and alcohol use disorder (AUD), and obesity.

MethodsThis study compared group differences in salient cue reactivity and eating behaviours between ex-smokers (n=25, ExS), adults with alcohol dependence who are abstinent (n=26, AAD), adults with obesity who were actively dieting (n=26, OB). Participants completed a high-energy food, preferred alcohol and cigarette functional magnetic resonance imaging (fMRI) cue reactivity task, along with eating behaviour questionnaires, appetite visual analogues scales and an ad libitum test meal.

ResultsExS exhibited greater blood oxygen level dependent (BOLD) signal to high-energy food pictures in several reward processing regions in both whole brain and region of interest (ROI) analyses, compared with the OB and AAD groups, with no difference in their appeal rating. Compared with the OB group, ExS exhibited greater BOLD signal to cigarette pictures in the frontal gyrus, orbitofrontal cortex, frontal pole and insula, with no difference in their appeal rating. There were no group differences in preferred alcohol cue reactivity. The AAD group rated sweet taste as more pleasant, and consumed more calories from sweet dishes in the ad libitum meal than the OB and ExS groups.

ConclusionsThe presence of heightened cue reactivity to high-energy foods in ex-smokers could contribute to post-quitting weight gain after smoking cessation. Neuroimaging findings were consistent with persistence of some salient drug cue reactivity, despite absence of craving, after medium term abstinence in ExS, but not in AAD. This study also adds to the body of evidence supporting a sweet taste preference endophenotype predisposing individuals to AUD. These changes in eating behaviour in NUD and AUD may provide targets for treatments to reduce substance misuse and facilitate abstinence.
]]></description>
<dc:creator><![CDATA[ Herlinger, K. E., Long, Y. Y., Nestor, L. J., Pannekoek, N. J., Al-Lababidi, M., Ertl, N., Vanelli, F., Chhibbar, P., Guerrero, E., Canizares, S., Akavarapu, S., Munafo, M. R., Lingford-Hughes, A. R., Nutt, D. J., Goldstone, A. P. ]]></dc:creator>
<dc:date>2026-03-16</dc:date>
<dc:identifier>doi:10.64898/2026.03.13.26348339</dc:identifier>
<dc:title><![CDATA[Salient cue reactivity and eating behaviours in ex-smokers, abstinent alcohol use disorder and obesity]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-16</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.12.26348300v1?rss=1">
<title>
<![CDATA[
Testing astrocyte alterations in chronic cocaine users: a longitudinal study using plasma glial fibrillary acidic protein 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.12.26348300v1?rss=1
</link>
<description><![CDATA[
Preclinical evidence indicates that cocaine exerts acute and chronic effects on astrocyte functioning, which in turn modulate cocaine-related impacts on neural integrity and brain function. However, human evidence for astrocytic involvement in cocaine users (CU) remains limited. Glial fibrillary acidic protein (GFAP) is a marker of astrocyte activation with promising clinical utility in neurological conditions, yet its relevance in the addiction field is unclear. Hence, we investigated plasma GFAP levels in chronic CU (n=41) and cocaine-naive controls (HC; n=34) at baseline and after a 4-month follow-up. GFAP was assessed alongside plasma neurofilament light chain (NfL) levels, a marker of neuroaxonal injury previously associated with cocaine use in the same sample. Contrary to our hypothesis, we found no group differences in plasma GFAP concentrations between CU and HC. Neither cross-sectional nor longitudinal associations between GFAP levels and objective indices of cocaine use (derived from hair testing) were detected. However, exploratory analyses revealed higher plasma GFAP levels among CU with recent cocaine consumption (within the last 7 days), suggesting transient astrocytic responses following acute exposure. Additionally, GFAP and NfL were positively correlated across participants, supporting their functional association. Overall, these findings suggest that while GFAP might not be chronically elevated in CU, it may exhibit transient increases related to recent cocaine use. Further research is warranted to characterize the temporal dynamics and biological significance of these glial responses.
]]></description>
<dc:creator><![CDATA[ Hunglinger, L. V., Eggenberger, L., Kexel, A.-K., Kluwe-Schiavon, B., Maceski, A., Baumgartner, M. R., Kuhle, J., Seifritz, E., Quednow, B. B., Bavato, F. ]]></dc:creator>
<dc:date>2026-03-14</dc:date>
<dc:identifier>doi:10.64898/2026.03.12.26348300</dc:identifier>
<dc:title><![CDATA[Testing astrocyte alterations in chronic cocaine users: a longitudinal study using plasma glial fibrillary acidic protein]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.03.26347368v1?rss=1">
<title>
<![CDATA[
Suicidality and Drug Use Behavior Among Perinatal Individuals in Recovery 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.03.26347368v1?rss=1
</link>
<description><![CDATA[
IntroductionMaternal mental health conditions, comprising maternal suicide and drug overdose, are currently the leading cause of maternal mortality in the United States. However, the relationship between suicidality and drug use behavior in the perinatal period is not well understood. We examined the association between suicidality and drug use behavior among perinatal individuals. Given the racial disparities in both drug use and suicide rates in the U.S., we also examined any differences in suicidality and drug use behavior by race.

MethodsParticipants were recruited from a High-Risk Obstetric & Gynecological Clinic in the Midwestern U.S that specializes in providing obstetric care to perinatal individuals who have histories or current use of opioids and other illicit drugs. Participants (N = 66) were a sub-sample of a larger cohort enrolled in an mHealth intervention to support recovery from opioid and stimulant use disorders. We performed chi-square tests and t-tests to examine any significant associations between lifetime suicidality and drug use behavior during the perinatal period.

ResultsThe final analytic sample included participants who had responded to the suicidality survey questions (n=43). Nearly 40% (n=16) of our sample endorsed a lifetime history of suicidal thoughts and behaviors (SITB). Of those, 87% (n=15) reported a previous suicide attempt. SITB was significantly associated with cravings for opioids during the perinatal period (p = .01) as well as comorbidities with perinatal anxiety symptoms? ( p < .05), depression symptoms? (p < .05), and bipolar disorder (p < .05). A higher proportion of recent cannabis use was found among mothers with SITB, compared to those without SITB (p=0.04). Mothers with SITB also had a strong positive correlation between preconception and postnatal nicotine use compared to mothers without SITB (p < .01). Finally, while white mothers endorsed more lifetime overdoses (p= 0.01), Black mothers endorsed higher cravings for opioids during pregnancy (p = 0.03).

ConclusionsA history of SITB is a distinct risk factor for both illicit and recreational drug use behavior in the perinatal period, and frequently co-occurs with other perinatal mental health conditions. Further research is needed to better understand the directionality of this relationship and the complex interplay between high risk drug use behavior and suicidality.
]]></description>
<dc:creator><![CDATA[ Constantino-Pettit, A., Li, X., Szlyk, H., Kasson, E., Cavazos-Rehg, P. ]]></dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.03.03.26347368</dc:identifier>
<dc:title><![CDATA[Suicidality and Drug Use Behavior Among Perinatal Individuals in Recovery]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.23.26346644v1?rss=1">
<title>
<![CDATA[
Brain penetrant calcium channel blockers do not reduce alcohol consumption: Converging results from two large independent cohort studies using electronic health records 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.23.26346644v1?rss=1
</link>
<description><![CDATA[
Alcohol use disorder (AUD) remains a major public health problem, with few effective medications and suboptimal adherence. L-type calcium channel blockers (LTCCBs) have genetic and preclinical support as potential treatments for AUD. We evaluated whether brain penetrant (BP)-LTCCBs are associated with reduced alcohol consumption by conducting two preregistered (https://osf.io/huawv) observational cohort studies using electronic health records (EHRs) from the US Department of Veterans Affairs (VA) and Kaiser Permanente Northern California (KPNC). New users of BP-LTCCBs (nifedipine or felodipine) were compared with new users of a non-BP-LTCCB (amlodipine) and with unexposed patients sampled from the same clinics, following a 180-day washout and requiring at least 60 days supply. Propensity score matching was conducted separately for BP-LTCCB versus unexposed, non-BP-LTCCB versus unexposed, and BP-versus non-BP-LTCCB. The primary outcome was change in drinks per week from the most recent pre-index screen to end of follow-up, estimated using difference-in-differences (DiD) models. Prespecified subgroup analyses were conducted by AUD diagnosis, baseline drinking level, and sex. Across both health systems, BP-LTCCB initiation was not associated with greater reductions in drinks per week than either comparator, with broadly consistent findings across all subgroups. In two large, preregistered EHR-based cohorts with rigorous confounding control, BP-LTCCBs were not associated with reduced drinking relative to comparators. Despite compelling genetic and preclinical evidence, these results do not support repurposing BP-LTCCBs for AUD, highlighting the need to prioritize alternative pharmacologic targets, potentially within etiologically informed subgroups.
]]></description>
<dc:creator><![CDATA[ Rentsch, C. T., Palzes, V., Shi, M., Setzer, M. R., Malone, S. G., Kline-Simon, A. H., Piserchia, Z., Winterland, E. L., Leggio, L., Lo Re, V., Fiellin, D. A., Tazare, J., Farokhnia, M., Sterling, S., Kranzler, H. R., Gray, J. C. ]]></dc:creator>
<dc:date>2026-03-02</dc:date>
<dc:identifier>doi:10.64898/2026.02.23.26346644</dc:identifier>
<dc:title><![CDATA[Brain penetrant calcium channel blockers do not reduce alcohol consumption: Converging results from two large independent cohort studies using electronic health records]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.27.26347207v1?rss=1">
<title>
<![CDATA[
Cannabis Use Documentation within the Electronic Health Record: A Use Case for Natural Language Processing Methods 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.27.26347207v1?rss=1
</link>
<description><![CDATA[
IntroductionRecreational and medical cannabis use (CU) information is often available within the electronic health record (EHR) in a format that is impractical for health care provider use. Transformation of free-text EHR documentation in notes to discrete elements is possible using natural language processing (NLP) and has the potential to characterize CU efficiently. The objective of this study was to develop an NLP algorithm to identify documentation of CU within EHR unstructured clinical notes.

MethodsWe identified EHR notes with cannabis-related terminologies through a keyword search among all Geisinger patients with at least one encounter between 1/1/2013 and 6/30/2022. We trained four NLP models to classify notes into six categories based on time, context, and reliability of CU documentation identified through manual annotation. We compared the demographic characteristics of patients with positive classification for CU using the best-performing model to those of the overall population.

ResultsOf the over 1.7 million eligible patients, 150,726 (8.6%) were flagged as cannabis users. The Bio-ClinicalBERT, a transformer-based NLP model, achieved close to human performance in classifying CU (weighted Precision=91.4, Recall=93.3, F-score=92.4). Cannabis users had higher BMI and were at least nine-fold more likely to use tobacco, alcohol, and illicit substances.

ConclusionOur study evaluated the prevalence of CU documentation across the entire corpus of EHR notes data without population segmentation. The NLP methodologies used achieved performance close to that of human annotation and laid the foundation for identifying and classifying CU within unstructured data sources, with future applications in research and patient care.

Plain Language SummaryMarijuana, also known as cannabis, may impact the health of patients, yet it is not routinely captured in medical records, and when documented, it is often found in unstructured formats (e.g., progress notes) rather than in discrete fields. Incomplete and unstructured capture limits many functional capabilities within the EHR that enhance patient care (e.g., drug interactions, notifications) and limit researchers from identifying patients routinely exposed to marijuana use. The transformation of free-text documentation of cannabis use (CU) into discrete elements can be performed using natural language processing (NLP). The objective of this study was to develop an NLP model to identify CU in unstructured clinical notes in the EHR. We examined the EHRs of Geisinger patients in Pennsylvania over a 10-year period. Among 1.7 million patients, 9% were identified as CU. One of the NLP models tested, Bio-ClinicalBERT, achieved the highest performance. Cannabis users had a higher BMI and were ten-fold more likely to be tobacco users, ten-fold more likely to use alcohol, and nine-fold more likely to use illicit substances. NLP can be used to better understand the risks and benefits of CU at a population level and may improve patient identification to assist clinical decision-making. Future CU epidemiological research should continue to explore other avenues to automate and improve CU documentation by leveraging rapidly evolving technologies, such as artificial intelligence-driven tools.
]]></description>
<dc:creator><![CDATA[ Pradhan, A. M., Shetty, V. A., Gregor, C., Graham, J. H., Tusing, L., Hirsch, A. G., Hall, E., Troiani, V., Davis, M. P., Bieler, D. L., Romagnoli, K. M., Kraus, C. K., Piper, B. J., Wright, E. A. ]]></dc:creator>
<dc:date>2026-03-02</dc:date>
<dc:identifier>doi:10.64898/2026.02.27.26347207</dc:identifier>
<dc:title><![CDATA[Cannabis Use Documentation within the Electronic Health Record: A Use Case for Natural Language Processing Methods]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.24.26347002v1?rss=1">
<title>
<![CDATA[
Classification of Adolescent Drinking via Behavioral, Biological, and Environmental Features: A Machine Learning Approach with Bias Control 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.24.26347002v1?rss=1
</link>
<description><![CDATA[
In 2024, approximately 30% of U.S. adolescents reported having consumed alcohol at least once in their lifetime, with about 25% of these individuals engaging in binge drinking. Adolescent alcohol use is associated with neurodevelopmental impairments, elevated risk of later alcohol use, and mental health disorders. These findings underscore the importance of identifying the variables driving adolescent alcohol use and leveraging them for early identification and targeted intervention. Previous studies have typically developed machine-learning classification models that use neuroimaging data in combination with limited clinical measurements. Neuroimaging data are expensive and difficult to obtain at scale, whereas clinical measures are more practical for large-scale screening due to their low cost and widespread accessibility. However, clinical-only approaches for alcohol drinking classification remain largely underexplored. Furthermore, prior studies have often focused on adults, limiting generalizability to the broader adolescent population. Additionally, confounding factors such as age and substance use, which are strongly correlated with alcohol consumption, have often been inadequately addressed, potentially inflating classification performance. Finally, class imbalance remains a persistent challenge, with prior attempts yielding only limited improvements. To address these limitations, we propose FocalTab, a framework that integrates TabPFN with focal loss for robust generalization and effective mitigation of class imbalance. The approach also incorporates an initial preprocessing step to remove confounding factors to account for age and substance-use. We compare FocalTab against state-of-the-art methods across different variable selections and dataset settings. FocalTab achieves the highest accuracy (84.3%) and specificity (80.0%) in the most stringent setting, in which both age and substance use variables were excluded, whereas competing models drop to near-chance specificity (12-24%). We further applied SHapley Additive exPlanations (SHAP) analysis to identify key clinical predictors of drinker classification, supporting enhanced screening and early intervention.
]]></description>
<dc:creator><![CDATA[ Liu, R., Azzam, M., Zabik, N., Wan, S., Blackford, J., Wang, J. ]]></dc:creator>
<dc:date>2026-02-26</dc:date>
<dc:identifier>doi:10.64898/2026.02.24.26347002</dc:identifier>
<dc:title><![CDATA[Classification of Adolescent Drinking via Behavioral, Biological, and Environmental Features: A Machine Learning Approach with Bias Control]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.19.26346573v1?rss=1">
<title>
<![CDATA[
Fighting Addictions, improving Lives through COmprehensive drug rehabilitation with music (FALCO): Protocol for an international randomised controlled trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.19.26346573v1?rss=1
</link>
<description><![CDATA[
BackgroundSubstance use disorders (SUD) are associated with a high global burden of disease, with 5.4% of all disability-adjusted life years lost due to alcohol and illicit drugs. Highly prevalent multimorbidity includes polysubstance use, mental health conditions, and other non-communicable and infectious diseases. Where traditional treatments are insufficient alone, music therapy (MT) is highly engaging and improves motivation and reduces craving; however, its long-term effects are unknown. The present study aims to examine long-term effects of active music groups (AMG) and music listening groups (MLG) versus treatment as usual (TAU) on addiction severity, recovery, and other outcomes in people with SUD Immediate and short-term effects, as well as mechanisms of these interventions, will also be examined.

MethodsIn individuals with SUD across a wide range of age, gender, socioeconomic, and cultural backgrounds, a parallel 3-arm assessor-blinded pragmatic multinational randomised controlled trial (RCT) with embedded exploratory trials and mechanistic studies will determine long-term effects of AMG and MLG versus TAU on addiction severity (primary endpoint: 1 year), recovery, and other outcomes. Embedded trials will examine immediate effects of AMG or MLG combined with individual components of TAU combined to determine the best combinations of interventions. Experimental studies will examine mechanisms using cognitive testing and brain imaging. With 600 participants in 7 countries randomised, the trial will have 80% power on the primary outcome. Patient representatives, health technology assessment (HTA) bodies, and interventionists have been involved from conception and will ensure feasibility and applicability of the intervention across Europe.

DiscussionThis document describes the FALCO RCT, the main part of the FALCO project, which aims to reduce disease burden through innovative, effective, and affordable treatment, and will strengthen research and innovation expertise. Recommendations from FALCO will inform intervention delivery across Europe and beyond, leading to increased safety, effectiveness, and cost-effectiveness, and improved quality of life for individuals with SUD. Stakeholders will be involved in communicating findings across all European countries and regions and ensuring that findings are effectively implemented.

Trial registrationClinicalTrials.gov, NCT07028983, registered 11th of June 2025. https://clinicaltrials.gov/study/NCT07028983
]]></description>
<dc:creator><![CDATA[ Geretsegger, M., Meling, H. M. K., Savinova, A., Assmus, J., Dy, C. L., Mydland, T. S., Dybdahl, K., Johansen, B., Koelsch, S., Malerbakken, A., Sommerbakk, M., Tuastad, L., Erga, A. H., Hetland, J., Karshikoff, B., Svendsen, T. S., Lien, L., Roer, G. E., Roste, H.-A., Seberg, A. W., Kocan, A. U., Pelowski, M., Scharnowski, F., Silani, G., Stankovic, M., Steyrl, D., Magel, F., Maisriml, R., Scheibenbogen, O., Fent, J., Stegemann, T., Gassner, L., Zechmeister-Koss, I., Gottfried, T., Bensimon, M., Ferreri, L., Figini, C., Fusar-Poli, L., Politi, P., Bidzan-Bluma, I., Bieleninik, Łucja, Makurat ]]></dc:creator>
<dc:date>2026-02-23</dc:date>
<dc:identifier>doi:10.64898/2026.02.19.26346573</dc:identifier>
<dc:title><![CDATA[Fighting Addictions, improving Lives through COmprehensive drug rehabilitation with music (FALCO): Protocol for an international randomised controlled trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.16.26346428v1?rss=1">
<title>
<![CDATA[
Disparities, Perceived Discrimination, and Patient-Clinician Communication in Alcohol Use Disorder Treatment: An All of Us Cohort Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.16.26346428v1?rss=1
</link>
<description><![CDATA[
Background and AimsAlcohol use disorder (AUD) remains a major public health concern, with persistent disparities in access to evidence-based treatment. This study aimed to examine associations between perceived discrimination in healthcare settings (PDHS), patient-clinician communication (PCC), and receipt of treatment for AUD, and compared these with sociodemographic and insurance-related factors.

DesignCross-sectional analysis using structural equation modeling (SEM), logistic and multinomial logistic regression, and machine learning approaches including SHapley Additive exPlanations (SHAP).

SettingUnited States, using data from the National Institutes of Health All of Us Research Program.

ParticipantsA total of 5,287 adults with AUD (mean age 61 years; 57% men), including 71.6% non-Hispanic White, 12.2% Black, and 8.6% Hispanic participants. Insurance coverage included 52% government (Medicaid/Medicare), 37% private, and 21% military with 19% reporting more than one type.

MeasurementsPrimary outcomes were receipt of Food and Drug Administration-approved pharmacotherapy and/or psychotherapy for AUD, examined as binary and multinomial outcomes. The primary exposure was PDHS, measured using a 7-item scale (range 7-35), with higher scores indicating more frequent discrimination. PCC, assessed using a 2-item scale (range 2-8) with higher scores indicating poorer communication, was examined as a potential mediator. Models were adjusted for age group, sex at birth, race/ethnicity, insurance type (government, private, military), household income, and Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores (range 0-12).

FindingsPDHS was associated with poorer PCC ({beta} = 0.209, p < 0.001), although communication was not independently associated with treatment receipt. The indirect pathway from discrimination to treatment via communication was not supported. Military insurance was the strongest predictor of treatment receipt, with 6-7 times higher odds compared with other insurance types. Higher AUDIT-C scores and greater PDHS were also associated with increased likelihood of treatment. In analyses restricted to civilian participants, PDHS showed a stronger association with treatment receipt, while PCC demonstrated more modest effects. Machine learning models identified PDHS, AUDIT-C, and PCC as strong contributors, with the impact of poor communication most pronounced among individuals with lower income.

ConclusionsAccess to treatment for alcohol use disorder is most strongly associated with insurance coverage, particularly military insurance. PDHS and PCC also contribute to treatment engagement, with differential effects across socioeconomic groups. These findings highlight the importance of addressing structural and interpersonal barriers to improve equitable access to evidence-based AUD treatment.
]]></description>
<dc:creator><![CDATA[ Moon, J., Espinoza, J. C. I., Puzantian, T. ]]></dc:creator>
<dc:date>2026-02-18</dc:date>
<dc:identifier>doi:10.64898/2026.02.16.26346428</dc:identifier>
<dc:title><![CDATA[Disparities, Perceived Discrimination, and Patient-Clinician Communication in Alcohol Use Disorder Treatment: An All of Us Cohort Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.16.26346220v1?rss=1">
<title>
<![CDATA[
Estimating the Smallest Worthwhile Difference (SWD) of Psychotherapy for Alcohol Use Disorder: Protocol for a Cross-Sectional Survey 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.16.26346220v1?rss=1
</link>
<description><![CDATA[
BackgroundPsychotherapy is proven efficacious for the treatment of alcohol use disorder (AUD). However, the patient-perceived importance of its effect is not fully appreciated in the evidence base. The smallest worthwhile difference (SWD) represents the smallest beneficial effect of an intervention that patients deem worthwhile in exchange for the harms, expenses, and inconveniences associated with the intervention, and facilitates the interpretation of patient perceived worthiness of an intervention.

MethodsThe proposed study will estimate the SWD of NIAAA recommended psychotherapies for AUD treatment with English-speaking American respondents aged 18 and older. Primary participants will be recruited using the Prolific research crowdsourcing site. The SWD will be estimated using the Benefit-Harm Trade-off Method, presenting survey respondents with variable, hypothetical magnitudes of psychotherapy outcomes to find the smallest acceptable effect over a natural recovery alternative. The overall average SWD, and subgroup distributions by participant AUD treatment experiences and AUD symptomology will be described. Secondary findings will estimate the smallest recommendable risk difference for AUD psychotherapy from providers and criminal justice professionals.

Expected ResultsWe expect to find an estimate of the SWD for AUD psychotherapy. Further, we expect that the SWD will vary between clinical subgroups based on AUD symptomology and treatment experiences. We expect differences in SWDs between the general population and those of providers and criminal justice professionals. Findings from this project will inform the treatment decision process about psychotherapy during the clinical consultation for people with AUD.
]]></description>
<dc:creator><![CDATA[ Sahker, E., Lu, I., Eddie, D., So, R., Luo, Y., Omae, K., Tajika, A., Angelo, J. P., Crisp, T., Coffin, B., Furukawa, T. A. ]]></dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.16.26346220</dc:identifier>
<dc:title><![CDATA[Estimating the Smallest Worthwhile Difference (SWD) of Psychotherapy for Alcohol Use Disorder: Protocol for a Cross-Sectional Survey]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.12.26346211v1?rss=1">
<title>
<![CDATA[
Mindfulness-Oriented Recovery Enhancement rebalances prefrontal responses to drug and natural reward cues in opioid use disorder 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.12.26346211v1?rss=1
</link>
<description><![CDATA[
Despite decades of clinical implementation of medications for opioid use disorder (OUD), overdose mortality rates remain high, underscoring a critical gap in treatments that target brain mechanisms driving addiction. Mindfulness-Oriented Recovery Enhancement (MORE) has demonstrated efficacy in reducing opioid use and craving, hypothetically by restructuring the salience of drug and natural rewards. Yet, to date, MOREs neurobiological mechanisms remain unclear. In this first functional magnetic resonance imaging (fMRI) randomized controlled trial (RCT) of MORE for OUD (NCT04112186), we tested whether compared with an active psychoeducational supportive therapy (PST) control group, MORE rebalanced neural responses to drug and natural reward cues in inpatients with OUD receiving standard of care including medications. Compared with PST, eight weeks of MORE significantly reduced drug-biased activity in the dorsolateral prefrontal cortex (dlPFC) and posterior regions of the default mode network including the precuneus during downregulation of responses to drug cues relative to upregulation of responses to natural reward cues (even when controlling for passive cue viewing). The shift from drug to natural reward responses in the lateral and ventromedial PFC was associated with lower cue-induced craving exclusively in the MORE group. MORE also reduced medial PFC synchronization to naturalistic drug-related movie scenes and significantly extended abstinence duration at follow-up ([~]4 months post-treatment) relative to PST. Together, this neuroimaging RCT demonstrates that MORE normalizes function in PFC nodes of the reward, salience, and control systems, positioning MORE as a biologically-grounded adjunct to pharmacotherapy for OUD.
]]></description>
<dc:creator><![CDATA[ Huang, Y., Ceceli, A. O., Kronberg, G., Drury, K. R., King, S. G., McClain, N. E., Wong, Y. Y., Boros, M., Butelman, E. R., Gaudreault, P.-O., Parvaz, M. A., Alia-Klein, N., Garland, E. L., Goldstein, R. Z. ]]></dc:creator>
<dc:date>2026-02-15</dc:date>
<dc:identifier>doi:10.64898/2026.02.12.26346211</dc:identifier>
<dc:title><![CDATA[Mindfulness-Oriented Recovery Enhancement rebalances prefrontal responses to drug and natural reward cues in opioid use disorder]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.12.26346166v1?rss=1">
<title>
<![CDATA[
Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder:A Translational Systematic Review and Meta-Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.12.26346166v1?rss=1
</link>
<description><![CDATA[
Tobacco use disorder (TUD) remains a leading cause of preventable mortality, and existing pharmacotherapies yield 12-month abstinence rates below 30%. As cannabis legalization expands, approximately 18-22% of people who use tobacco report concurrent cannabis use, yet the impact of co-use on cessation outcomes and the therapeutic potential of endocannabinoid system (ECS) modulation remain unclear. We conducted a translational systematic review and meta-analysis following PRISMA 2020 guidelines, searching Ovid MEDLINE, Embase, APA PsycInfo, and Web of Science through January 2026 (PROSPERO: CRD420250652724). Three study categories were eligible: observational studies of cannabis co-use and cessation outcomes; preclinical studies of cannabinoid modulators on nicotine-related behaviors; and human experimental studies of ECS-targeted interventions. Of 4,869 records screened, 52 studies met inclusion criteria. Meta-analysis of 18 observational studies (N=229,630) revealed that cannabis use was associated with 35% lower odds of achieving tobacco cessation (OR=0.65; 95% CI: 0.55-0.78; p<0.0001; I{superscript 2}=88.1%). Preclinical evidence (15 studies) demonstrated that CB1 receptor antagonists robustly reduced nicotine self-administration and reinstatement, while cannabidiol (CBD) attenuated both nicotine intake and withdrawal without affecting food reinforcement. Clinical translation of CB1 receptor inverse agonists failed due to psychiatric adverse effects, but CBD showed promise by reducing cigarette consumption by 40%, reversing attentional bias to smoking cues, and alleviating withdrawal severity. These findings distinguish naturalistic cannabis exposure from potentially beneficial targeted ECS modulation, and support CBD as a promising candidate for adequately powered tobacco cessation trials.
]]></description>
<dc:creator><![CDATA[ P. A. Costa, G., Gomez, O., A. Cerezo-Matias, M., C. Funaro, M., Sofuoglu, M., De Aquino, J. P. ]]></dc:creator>
<dc:date>2026-02-14</dc:date>
<dc:identifier>doi:10.64898/2026.02.12.26346166</dc:identifier>
<dc:title><![CDATA[Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder:A Translational Systematic Review and Meta-Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.10.26346048v1?rss=1">
<title>
<![CDATA[
Targeting Cortico-Striatal-Amygdalar Networks via Theta-Band Frontoparietal Synchronization in Opioid Use Disorder: A Randomized tACS-fMRI Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.10.26346048v1?rss=1
</link>
<description><![CDATA[
BackgroundTheta-band oscillation is integral to fronto-parietal connectivity in the executive control network and its top-down regulation on subcortical areas. External frontoparietal synchronization using theta-frequency transcranial alternating current (tACS) is a technology to potentially engage this network. In this pre-registered, triple-blind, sham-controlled trial (NCT03907644), we tested this intervention targeting the right frontoparietal network in people with opioid use disorder (OUD) to measure network engagement and behavioral outcomes.

MethodSixty male participants with OUD were randomized to receive 20 minutes of active or sham 6 Hz tACS (HD electrodes over F4 and P4). Structural, resting-state, task-based fMRI drug cue reactivity, and repeated cue-induced craving assessments were collected immediately before and after stimulation. Pre-registered outcome measures were analyzed using timexgroup interaction models to examine (1) modulation of drug cue-related brain activity, (2) changes in craving, (3) alterations in functional connectivity, and (4) relationship between electric field, neural responses, and craving behavior.

Results(1) A significant Time x Group interaction revealed decreased post-stimulation opioid cue-related activity in the active group relative to sham, involving key nodes in reward processing (ventral striatum, amygdala and ventral tegmental area) (FWE corrected =0.05) (2) subjective craving did not differ significantly between groups (3) Group by time generalized psychophysiological interaction analyses showed increased right frontoparietal network engagement ({beta}=2.63, p=0.0308) following stimulation, and increased top-down inhibitory regulation of frontoparietal network on right ventral striatum ({beta}=1.99, p=0.037) and left medial amygdala ({beta}=1.97, p=0.039) (4) Electric field strength in the right frontal/parietal node predicted frontoparietal network engagement in the active group (r=0.43, p=0.02).

ConclusionTogether, these findings demonstrate that theta-band frontoparietal tACS can modulate activity and task-dependent coupling within cortical-subcortical circuits in OUD, supporting network-targeted neuromodulation as a potential intervention for addiction.

Significance StatementAddiction is linked to imbalances in cortico-subcortical brain circuits that control reward processing and craving. This study tested whether a non-invasive brain stimulation method-- theta-band transcranial alternating current stimulation (tACS)--can rebalance these circuits in people with opioid use disorder. Using advanced brain imaging, we found that tACS strengthened communication within frontoparietal brain regions involved in self-control while reducing their connections with reward and emotion centers. These brain changes were linked to reduced craving responses to drug cues. Our results demonstrate that dual-site, network-targeted tACS modulates neural activity and task-dependent engagement of brain circuits during drug cue reactivity in addiction, supporting its potential as a novel therapeutic approach.
]]></description>
<dc:creator><![CDATA[ Soleimani, G., Kuplicki, R., Paulus, M. P., Ekhtiari, H. ]]></dc:creator>
<dc:date>2026-02-11</dc:date>
<dc:identifier>doi:10.64898/2026.02.10.26346048</dc:identifier>
<dc:title><![CDATA[Targeting Cortico-Striatal-Amygdalar Networks via Theta-Band Frontoparietal Synchronization in Opioid Use Disorder: A Randomized tACS-fMRI Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-11</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.05.26345663v1?rss=1">
<title>
<![CDATA[
Patient Perspectives on Buprenorphine Treatment for Opioid Use Disorder and Preferences for Long-Acting Injectable Formulations: Findings from a National Online Survey 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.05.26345663v1?rss=1
</link>
<description><![CDATA[
BackgroundLong-acting injectable buprenorphine (LAIB) has been positioned as a potentially transformative option for opioid use disorder (OUD), in part because patient experiences reported in qualitative studies emphasize reduced daily burden, increased "freedom," reduced stigma, and fewer pressures related to diversion--while also noting barriers such as insufficient information, early adverse experiences, and concerns about coercion.

MethodsWe conducted a cross-sectional online survey of adults recruited from the Behavioral Health Research Panel (BHRP). Eligibility included age [&ge;]18, English literacy, and OUD diagnosis or problematic opioid use within the past 5 years. Survey content assessed buprenorphine experience, knowledge and attitudes toward LAIB, attribute preferences, and open-text feedback. Descriptive statistics were generated; analyses were stratified by buprenorphine experience (experienced vs naive).

ResultsAmong 105 participants, 82.9% reported prior buprenorphine use, and 17.1% were buprenorphine-naive. Overall, 53.3% preferred a long-acting injection regimen (weekly/monthly/3-monthly) versus 46.7% preferring a daily oral tablet/film. Convenience and adherence-related themes (e.g., not missing doses, fewer visits) drove LAIB preference, while oral-route preference and concerns about side effects and safety were prominent among those favoring oral formulations.

ConclusionsIn this national convenience sample, preferences were nearly evenly split between daily oral and long-acting injectable buprenorphine regimens, with a slight overall preference for LAIB. Findings align with the qualitative literature, emphasizing the practical and psychosocial benefits of LAIB, alongside persistent needs for improved education, shared decision-making, and attention to tolerability, safety perceptions, and cost/coverage barriers.
]]></description>
<dc:creator><![CDATA[ Oesterle, T. S., Bormann, N. S. ]]></dc:creator>
<dc:date>2026-02-06</dc:date>
<dc:identifier>doi:10.64898/2026.02.05.26345663</dc:identifier>
<dc:title><![CDATA[Patient Perspectives on Buprenorphine Treatment for Opioid Use Disorder and Preferences for Long-Acting Injectable Formulations: Findings from a National Online Survey]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.03.26345434v1?rss=1">
<title>
<![CDATA[
Self-reported impulsivity, task-based inhibitory control, and early sipping behaviors as longitudinal predictors of adolescent alcohol use and problems in the ABCD Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.03.26345434v1?rss=1
</link>
<description><![CDATA[
BackgroundEarly low-level alcohol use predicts subsequent alcohol use and problems. Impulsivity and poor inhibitory control also predict later problematic alcohol use. However, few studies prospectively examine early sipping in combination with modeling impulsivity and inhibitory control change over time as predictors of adolescent alcohol use.

MethodsData Release 6.0 from the Adolescent Brain Cognitive Development (ABCD) Study was used (n=11,866; 48% Female). A series of linear mixed-effect models examined trajectories of non-religious sipping at baseline (ages 9-10) and self-reported impulsivity (UPPS-P) and task-based inhibitory control (Flanker task) over time as predictors of past year drinks and problematic alcohol use by ages 15-16. Predictors were run as separate models and a full model with all predictors together. Models were nested within the participant and study site. Interactions with age (to measure change over time from Baseline to Year 6) were included. Corrections for multiple comparisons were employed.

ResultsIn individual models, four impulsivity interactions were significant: (1) negative urgency*age ({beta}=.04, FDR-p<.001), (2) positive urgency*age ({beta}=.04, FDR-p<.001), (3) lack of planning*age ({beta}=.04, FDR-p<.001), and (4) sensation seeking*age ({beta}=.04, FDR-p<.001), suggesting that as age increases, the relationship between impulsivity and alcohol use strengthens. Sipping*age ({beta}=.02, FDR-p<.001) interactions also predicted standard drinks. Regarding problematic use, there was a significant interaction in the full model: negative urgency*age ({beta}=-.07, p=.05), indicating that this relationship is more pronounced at earlier ages.

ConclusionsTrait impulsivity and sipping in late childhood relate to future alcohol use, and the relationship strengthens with age. Our results found a negative interaction between negative urgency and age on problematic use, potentially indicating negative urgency as a phenotype of vulnerability to experiencing alcohol related problems at younger ages. Findings indicate the importance of understanding facets of impulsivity in the context of adolescent alcohol use for prevention and intervention efforts.
]]></description>
<dc:creator><![CDATA[ Szpak, V., Delfel, E. L., Wallace, A. L., Sullivan, R. M., Jacobus, J., Tapert, S. F., Wade, N. E. ]]></dc:creator>
<dc:date>2026-02-04</dc:date>
<dc:identifier>doi:10.64898/2026.02.03.26345434</dc:identifier>
<dc:title><![CDATA[Self-reported impulsivity, task-based inhibitory control, and early sipping behaviors as longitudinal predictors of adolescent alcohol use and problems in the ABCD Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-04</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
